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DOES WEIGHT LOSS ADD VALUE TO BLOOD PRESSURE CONTROL AMONG
PATIENTS WITH DIABETIC KIDNEY DISEASE?
Uptal Patel, Shelby Reed
Duke Clinical Research Institute, Durham, North Carolina.
Obesity is an independent risk factor for development and progression of
diabetic kidney disease (DKD). Whether weight loss provides any additional
beneﬁt beyond blood pressure (BP) control is unclear. To simulate a trial, we
used the Archimedes model, a person-speciﬁc simulation model including
detailed representations of physiology, diseases, and health care systems. Our
population-based sample represented individuals diagnosed with type
2 diabetes and DKD drawn from 1999-2006 cohorts of NHANES. Simulations
were generated to estimate costs and health outcomes across time for
3 treatment strategies: (1) standard of care (STD); (2) blood pressure control
(BP); and (3) BP combined with 5% weight loss (BPWT). BP control represents
3.5%&6% reductions for those with SBP4130 and SBP4140, respectively. Over
a 20y time horizon, discounted costs for the STD group were $165,261 with
discounted quality adjusted life-years (QALYs) of 5.89. With BP estimated at
$30/month, the incremental cost-effectiveness ratio (ICER) was $26,626/QALY
compared to STD. With BPWT at $50/month, the ICER was $31,773 compared
to STD. Even with varying intervention costs and durations (Figure), the ICERs
remained favorable, especially for the BPWT group.In conclusion, weight loss in
addition to BP control appears to provide favorable value, particularly over
moderate time horizons.
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VITAMIN D SUFFICIENCY IN HEMODIALYSIS PATIENTS AND ITS
ASSOCIATION WITH NUTRITIONAL AND CLINICAL PARAMETERS
Barbara Perez Vogt, Francieli Delatim Vannini, Aline Araujo Antunes,
Jo~ao Henrique Castro, Pasqual Barretti Jacqueline
Teixeira Caramori. Botucatu Medical School, S ~ao Paulo State University, Brazil
Renal failure is a complicating factor in the maintenance of vitamin D
adequate levels, which can interfere in the patients’ nutritional status. The
aim of this study was to evaluate the association of serum 25-
hydroxyvitamin D [25(OH)D] with clinical and nutritional parameters.
Prevalent hemodialysis (HD) patients were submitted to a single
evaluation about demographic characteristics, clinical data and laboratory
measurements. Anthropometric measurements and electrical
bioimpedance were performed to obtain BMI, percentage of standard
MAMC (%MAMC), fat percentage (%Fat) and phase angle (PA). Deﬁciency
was deﬁned as a 25(OH)D levelo15 ng/mL, insufﬁciency as 15-30 ng/mL
and sufﬁciency as430 ng/mL. Univariate models were constructed and the
variables associated with 25(OH)D sufﬁciency were included subsequentlyin the multiple regression model. Statistical signiﬁcance was po0.05.One
hundred twelve patients (59 male, 53 female) were included. Twenty seven
(24.1%) were 25(OH)D deﬁcient, 43 (38.4%) insufﬁcient and 42 (37.5%)
sufﬁcient. In univariate regression, creatinin, albumin and PA were
positively associated with serum 25(OH)D, while age, glucose, BMI and
%MAMC were negatively associated. In multivariate regression, age and
%MAMC were negatively associated with sufﬁciency. Most studied sample
showed inadequate 25(OH)D levels. In our study, the result to be
highlighted was the negative associations of 25(OH)D sufﬁciency with age
and %MAMC, but all the ﬁndings suggest that fat interferes with vitamin D
stores in HD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.520197
RELATIONSHIPS AMONG EGFR, VITAMIN D METABOLITES AND PTH 1-84
IN CKD.
K. Phelps, R. Mathew, K. Stote, L. Hewson, D. Hallenbeck
Stratton VAMC and Albany Medical College, Albany, NY, USA.
Vitamin D undergoes 25-hydroxylation in the liver (25D) and 1-alpha
hydroxylation in the kidney (1,25D). Both [25D] and [1,25D] fell with GFR
in surveys of patients with CKD. Because 1,25D suppresses transcription of
the PTH gene, low [1,25D] is thought to be a cause of high [PTH] in CKD. To
examine relationships among eGFR, [PTH] 1–84 (Scantibodies), [25D], and
[1,25D], we studied 8 normal subjects with eGFR 73–103 and 29 patients
with eGFR 14–49 ml/min/1.73 m2. Most patients had been taking
supplemental vitamin D. Means (SEM) were compared by two-tailed t-test,
and regressions were examined as indicated below. Results are
summarized in the tables.Variable CKD (n¼29) Nl (n¼8) peGFR (ml/min/1.73 m2) 30.0 (1.7) 88.6 (4.0) o 0.001
[PTH] pg/ml 80.6 (8.6) 30.1 (3.7) 0.005
[25D] ng/ml 35.2 (2.5) 39.7 (3.4) 0.4
[1,25D] pg/ml 42.5 (3.6) 55.1 (4.8) 0.1CKD (n¼29) Nl (n¼8)Regression R2 p R2 p[PTH] on eGFR 0.36 o 0.001 0.13 0.4
[25D] on eGFR 0.001 0.9 0.01 0.8
[1,25D] on eGFR 0.20 0.014 0.12 0.4
[1,25D] on [25D] 0.37 o 0.001 0.18 0.3
[PTH] on [25D] 0.02 0.5 0.03 0.7
[PTH] on [1,25D] 0.03 0.4 0.003 0.9In comparison to normal subjects, patients with CKD had lower eGFR,
higher [PTH], and similar [25D] and [1,25D]. In the patients with CKD,
[1,25D] varied directly and [PTH] inversely with eGFR. Unlike [1,25D],
[25D] was not associated with eGFR, but [1,25D] nevertheless correlated
strongly with [25D]. [PTH] was not related to [25D] or [1,25D]. In our
patients with CKD, many of whom were vitamin D-replete, [25OHD] was
the principal determinant of [1,25D]. Increased [PTH] could not be
attributed to decreased [1,25D].
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PROFILE OF SERUM AMINO ACIDS IN PATIENTS ON
PERITONEAL DIALYSIS
Inna Pichugina, Olga Vetchinnikova, M.F Vladimirsky
Moscow Regional Clinical and Research Institute, Russia
Patients on peritoneal dialysis (PD) are predisposed to disturbances in
amino acid metabolism and development of malnutrition which are
unfavorable prognostic factors. Studying the serum level of essential amino
acids in patients on PD. The total of 56 PD patients (mean age 42.4711.5
years, treatment duration 24.0714.2 months) was examined
simultaneously with 12 practically healthy volunteers (mean age
39.4710.7 years). Analysis of the dietary interviews and 3-day dietary
journals was carried out. The levels of essential and conditionally essential
